Skip to content

Electronic Triggers: Microhematuria Trigger

Electronic Trigger for Microhematuria

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05011253
Enrollment
2000
Registered
2021-08-18
Start date
2021-10-06
Completion date
2022-06-06
Last updated
2022-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematuria

Brief summary

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders.

Detailed description

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).

Interventions

OTHERElectronic Trigger Microhematuria Alert

To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 35 years of age or older * 3+ RBC on Urinalysis * Urinalysis sent during an outpatient encounter * any of the following: 60 years of age or older; RBC \> 25; current or prior tobacco use; Gross Hematuria

Exclusion criteria

* Under 35 years of age * Cystoscopy within 1 year prior to Urinalysis * Nitrite positive AND Leukocyte Esterase positive * Nitrite positive AND \>100 WBC * Leukocyte Esterase positive AND \>100 WBC * Know GU cancer diagnosis * Urinalysis ordered by urology provider

Design outcomes

Primary

MeasureTime frameDescription
Evaluation rate180 days of alertUrology evaluation with cystoscopy and appropriate imaging

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026